Last checked at 
NetScientific PLC - life sciences and technology investment and commercialisation company - Shares restored following announcement that portfolio company PDS Biotechnology Corp's phase 2 study has achieved its preliminary objective response. The study is of PDS0101 in advanced human papillomavirus or HPV-associated cancers that have progressed or returned following treatment.
The trial now progresses to full enrolment of around 20 patients who are checkpoint inhibitor naive and around 20% who have failed prior therapy with checkpoint inhibitors.
NetScientific Non-Executive Director Stephen Smith: "Over the last year PDS has made significant progress in developing its pipeline of cancer immunotherapies and infectious disease vaccines based on the company's proprietary Versamune T-cell activating technology platform. These preliminary results show the promise of PDS' approach in the personalised cancer care space."
Current stock price: 51.00 pence; up 8.5%
Year-to-date change: up 9.7%
By Anna Farley; annafarley@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
